Logo Cytek Biosciences, Inc.

Cytek Biosciences, Inc. (CTKB) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
Cytek Biosciences, Inc. · Health Care · ref. ETF XLV · 36 calls · price $4.62
🔔Price alertsCreate an alert →
What the company does: Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.

📈 Cytek Biosciences, Inc. (CTKB) stock price

$4.62+10.8% over range
Aug 28, 25low $3.36 · high $5.88Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
50% recommend buying · 2 analysts
📊 JPI status : Cytek Biosciences, Inc. has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 CTKB price target & analyst consensusprice $4.62

The price target · all analysts combined (2 targets)
Highest target · 1 firm of 2$5.5+19.0%
Median target · of 2 targets$5.12+10.8%
Lowest target · 1 firm of 2$4.75+2.8%
Current price$4.62
⭐ What the most reliable analysts say

No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.

The consensus · 2 ratings (last 6 months)
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Cytek Biosciences, Inc.? The JPI assistant answers using our backtest data.

🔎 Detailed analyses

✅ Historical analyst reliability on CTKB

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
Stephens & Co.  50% -10.0% 2
Piper Sandler  10% -27.4% 10
Goldman Sachs  0% -24.3% 9

📊 What $1,000 invested in Cytek Biosciences, Inc. would be worth › open the full page

In short — $1,000 invested in Cytek Biosciences, Inc. 10 years ago would be worth $246 today, i.e. -24%/yr on average. Best year: 2023 (-11%), worst: 2022 (-37%). Price performance, excluding dividends.

If I'd invested $1,000 in Cytek Biosciences, Inc.

InvestmentWorth todayGain
1 years ago$676-32%
3 years ago$452-55%
5 years ago$246-75%
→ See Cytek Biosciences, Inc.'s full return history + gain calculator

Return by year (Cytek Biosciences, Inc.)

YearReturn$1,000 invested at year start
2026 (YTD)-6%$939 (-6%)
2025-28%$676 (-32%)
2024-25%$507 (-49%)
→ See Cytek Biosciences, Inc.'s full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Cytek Biosciences, Inc.

Loading news…

📋 All analyst calls on CTKB

Stephens & Co. 
May 13, 26
▲ Overweight · 🎯$4.75
Price at call : $3.36 — upside +41%
Today : $4.62 — upside +3%
🎯 on CTKB : 50% (2 calls matureds) · 📊 on Health : 46.4% · +3.2% (84 calls)
in progress (365j)
matures : May 13, 27
Morgan Stanley 
May 12, 26
■ Equal-Weight neutral · not a buy · 🎯$5.5
Price at call : $3.68 — gap to target +49%
Today : $4.62 — gap to target +19%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 12, 27
TD Cowen 
Jan 8, 26
▲ Buy · 🎯$5
Price at call : $5.45 — upside -8%
Today : $4.62 — upside +8%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.3% · -0.8% (38 calls)
in progress (365j)
matures : Jan 8, 27
Piper Sandler 
Nov 11, 25
▲ Overweight · 🎯$7.5
Price at call : $4.81 — upside +56%
Today : $4.62 — upside +62%
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
in progress (365j)
matures : Nov 11, 26
Morgan Stanley 
May 28, 25
■ Equal-Weight neutral · not a buy · 🎯$7
Price at call : $2.59 — gap to target +170%
Today : $4.62 — gap to target +52%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 28, 26
Goldman Sachs 
May 12, 25
▼ Sell · 🎯$3
Price at call : $2.98 — upside +1%
Today : $4.62 — upside -35%
Expected +1% · Actual +23% · Reason (≤ −15%) : ✗ No
🎯 on CTKB : 0% (9 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-23.5%
stock +23% · XLV +11%
matured May 12, 26
Stephens & Co. 
Mar 19, 25
▲ Overweight · 🎯$6
Price at call : $4.06 — upside +48%
Today : $4.62 — upside +30%
Expected +48% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 50% (2 calls matureds) · 📊 on Health : 46.4% · +3.2% (84 calls)
+10.3%
stock +10% · XLV -1%
matured Mar 19, 26
Piper Sandler 
Mar 4, 25
▲ Overweight · 🎯$8
Price at call : $4.47 — upside +79%
Today : $4.62 — upside +73%
Expected +79% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
-2.0%
stock -2% · XLV +3%
matured Mar 4, 26
See the other 28 calls, newest to oldest
Piper Sandler 
Nov 11, 24
▲ Overweight · 🎯$8.5
Price at call : $7.15 — upside +19%
Today : $4.62 — upside +84%
Expected +19% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
-33.0%
stock -33% · XLV +1%
matured Nov 11, 25
Piper Sandler 
Aug 13, 24
▲ Overweight · 🎯$8
Price at call : $5.35 — upside +50%
Today : $4.62 — upside +73%
Expected +50% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
-22.1%
stock -22% · XLV -12%
matured Aug 13, 25
Piper Sandler 
May 13, 24
▲ Overweight · 🎯$8.5
Price at call : $6.18 — upside +38%
Today : $4.62 — upside +84%
Expected +38% · Actual -52% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
-51.8%
stock -52% · XLV -8%
matured May 13, 25
Piper Sandler 
Mar 6, 24
▲ Overweight · 🎯$10
Price at call : $7.07 — upside +41%
Today : $4.62 — upside +116%
Expected +41% · Actual -37% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
-36.9%
stock -37% · XLV +2%
matured Mar 6, 25
Goldman Sachs 
Feb 29, 24
▲ Buy · 🎯$10
Price at call : $9.15 — upside +9%
Today : $4.62 — upside +116%
Expected +9% · Actual -53% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 0% (9 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-53.0%
stock -53% · XLV +2%
matured Feb 28, 25
Stephens & Co. 
Dec 14, 23
▲ Overweight · 🎯$9
Price at call : $8.92 — upside +1%
Today : $4.62 — upside +95%
Expected +1% · Actual -30% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 50% (2 calls matureds) · 📊 on Health : 46.4% · +3.2% (84 calls)
-30.4%
stock -30% · XLV +4%
matured Dec 13, 24
■ Equal-Weight neutral · not a buy · 🎯$7
Price at call : $4.78 — gap to target +46%
Today : $4.62 — gap to target +52%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Nov 8, 24
Morgan Stanley 
Oct 24, 23
■ Equal-Weight neutral · not a buy · 🎯$8
Price at call : $4.75 — gap to target +68%
Today : $4.62 — gap to target +73%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Oct 23, 24
Piper Sandler 
Oct 16, 23
▲ Overweight · 🎯$10
Price at call : $5.13 — upside +95%
Today : $4.62 — upside +116%
Expected +95% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
+4.5%
stock +4% · XLV +17%
matured Oct 15, 24
Raymond James 
Jul 19, 23
■ Market Perform neutral · not a buy
🎯 on CTKB : no call matured yet · 📊 on Health : 39.9% · -2.0% (218 calls)
in progress (365j)
matures : Jul 18, 24
Morgan Stanley 
May 11, 23
■ Equal-Weight neutral · not a buy · 🎯$13
Price at call : $8.12 — gap to target +60%
Today : $4.62 — gap to target +181%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 10, 24
Goldman Sachs 
May 10, 23
▲ Buy · 🎯$12
Price at call : $8.86 — upside +35%
Today : $4.62 — upside +160%
Expected +35% · Actual -30% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 0% (9 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-30.1%
stock -30% · XLV +8%
matured May 9, 24
Piper Sandler 
Mar 7, 23
▲ Overweight · 🎯$15
Price at call : $9.83 — upside +53%
Today : $4.62 — upside +225%
Expected +53% · Actual -27% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
-27.2%
stock -27% · XLV +16%
matured Mar 6, 24
■ Equal-Weight neutral · not a buy · 🎯$14
Price at call : $10.61 — gap to target +32%
Today : $4.62 — gap to target +203%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Mar 1, 24
Goldman Sachs 
Mar 2, 23
▲ Buy · 🎯$14
Price at call : $9.64 — upside +45%
Today : $4.62 — upside +203%
Expected +45% · Actual -5% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 0% (9 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-5.1%
stock -5% · XLV +15%
matured Mar 1, 24
Piper Sandler 
Aug 18, 22
▲ Overweight · 🎯$16
Price at call : $14.06 — upside +14%
Today : $4.62 — upside +246%
Expected +14% · Actual -40% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
-39.8%
stock -40% · XLV +1%
matured Aug 18, 23
Morgan Stanley 
Aug 12, 22
■ Equal-Weight neutral · not a buy · 🎯$15
Price at call : $14.9 — gap to target +1%
Today : $4.62 — gap to target +225%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Aug 12, 23
Goldman Sachs 
Aug 11, 22
▲ Buy · 🎯$17
Price at call : $14.83 — upside +15%
Today : $4.62 — upside +268%
Expected +15% · Actual -37% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 0% (9 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-36.7%
stock -37% · XLV +3%
matured Aug 11, 23
Goldman Sachs 
Jul 14, 22
▲ Buy · 🎯$15
Price at call : $12.03 — upside +25%
Today : $4.62 — upside +225%
Expected +25% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 0% (9 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-25.2%
stock -25% · XLV +1%
matured Jul 14, 23
Piper Sandler 
May 16, 22
▲ Overweight · 🎯$12
Price at call : $9.9 — upside +21%
Today : $4.62 — upside +160%
Expected +21% · Actual -30% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
-30.4%
stock -30% · XLV +1%
matured May 16, 23
Morgan Stanley 
May 13, 22
■ Equal-Weight neutral · not a buy · 🎯$11
Price at call : $9.38 — gap to target +17%
Today : $4.62 — gap to target +138%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 13, 23
Goldman Sachs 
May 12, 22
▲ Buy · 🎯$12
Price at call : $8.13 — upside +48%
Today : $4.62 — upside +160%
Expected +48% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 0% (9 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-7.9%
stock -8% · XLV +4%
matured May 12, 23
Goldman Sachs 
Apr 13, 22
▲ Buy · 🎯$14
Price at call : $10.55 — upside +33%
Today : $4.62 — upside +203%
Expected +33% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 0% (9 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-2.4%
stock -2% · XLV -3%
matured Apr 13, 23
Morgan Stanley 
Feb 15, 22
■ Equal-Weight neutral · not a buy · 🎯$18
Price at call : $14.99 — gap to target +20%
Today : $4.62 — gap to target +290%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Feb 15, 23
Cowen & Co.
Aug 17, 21
▲ Outperform
Actual -37% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 0% (1 call matured) · 📊 unranked overall
-36.8%
stock -37% · XLV -2%
matured Aug 17, 22
Morgan Stanley 
Aug 17, 21
■ Equal-Weight neutral · not a buy · 🎯$26
Price at call : $21.78 — gap to target +19%
Today : $4.62 — gap to target +463%
🎯 on CTKB : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Aug 17, 22
Goldman Sachs 
Aug 17, 21
▲ Buy · 🎯$28
Price at call : $21.78 — upside +29%
Today : $4.62 — upside +506%
Expected +29% · Actual -35% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 0% (9 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-35.4%
stock -35% · XLV -3%
matured Aug 17, 22
Piper Sandler 
Aug 17, 21
▲ Overweight · 🎯$28
Price at call : $21.78 — upside +29%
Today : $4.62 — upside +506%
Expected +29% · Actual -35% · Reason (≥ +15%) : ✗ No
🎯 on CTKB : 10% (10 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
-35.4%
stock -35% · XLV -3%
matured Aug 17, 22

Frequently asked questions

Should I buy Cytek Biosciences, Inc. stock?

This isn't buy advice. For Cytek Biosciences, Inc., the analyst consensus is "Buy", with an average price target of $5.12 (+11% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 50% of the time (2 calls tracked on Cytek Biosciences, Inc.). We show the numbers — you decide.

Is it too late to buy Cytek Biosciences, Inc.? How high can it go?

The most bullish analyst target on Cytek Biosciences, Inc. is $5.50 (+19% above today's price); the average is $5.12. That's the upside they see. Check how reliable those analysts have actually been on Cytek Biosciences, Inc. on our site before trusting it.

Is Cytek Biosciences, Inc. still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 3 analysts have a real record on Cytek Biosciences, Inc., the best hitting 50% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

What has Cytek Biosciences, Inc.'s past performance been?

Historical returns and a "how much if I had invested" calculator: CTKB performance & returns.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)